Q3 2021 Cytokinetics Inc Earnings Call Transcript
Good afternoon, and welcome, ladies and gentlemen, to Cytokinetics' Third Quarter 2021 Conference Call. At this time, I would like to inform you that this call is being recorded. (Operator Instructions)
I will now turn the call over to Joanna Siegall, Cytokinetics' Senior Manager of Corporate Communications and Investor Relations. Please go ahead.
Good afternoon, and thanks for joining us on the call today. Robert Blum, our President and Chief Executive Officer, will begin with an overview of the quarter and recent developments; then Fady Malik, our EVP of Research and Development, will provide an update on omecamtiv mecarbil, including recently presented additional analyses for GALACTIC-HF, as well as an update on our ongoing next steps with the FDA.
Next, Stuart Kupfer, our SVP and Chief Medical Officer, will provide an update on our development program for aficamten by recapping the results from Cohorts 1 and 2 of REDWOOD-HCM, elaborating on continuing activities in REDWOOD-HCM and reviewing the design of SEQUOIA-HCM, our planned
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |